Xiaoqing Liu
A5109417430- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Respiratory Support and Mechanisms
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Brain Metastases and Treatment
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Thermal Regulation in Medicine
- Neonatal Respiratory Health Research
- HER2/EGFR in Cancer Research
- Nosocomial Infections in ICU
- Intensive Care Unit Cognitive Disorders
- Cancer Mechanisms and Therapy
- Climate Change and Health Impacts
- Medical Imaging and Pathology Studies
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Pleural and Pulmonary Diseases
Peking Union Medical College Hospital
2019-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2015-2025
Academy of Military Medical Sciences
2012-2024
Nanchang Center for Disease Control and Prevention
2024
Innovation Team (China)
2024
Beijing Proteome Research Center
2024
Chinese PLA General Hospital
2019-2024
Hebei University
2024
PLA 306 Hospital
2012-2023
307th Hospital of Chinese People’s Liberation Army
2013-2023
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Patients who failed from first-line EGFR-TKIs did not harbor T790M mutation were enrolled. Toripalimab carboplatin pemetrexed administrated every three weeks for up six cycles, followed by maintenance pemetrexed. The primary endpoint was objective-response rate (ORR). Integrated biomarker...
This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.Patients with advanced that progressed crizotinib were randomized 1:1 to 180 mg once daily (7-d lead-in, 90 mg) or 600 twice daily, aiming test superiority. The primary end point was blinded independent review committee-assessed progression-free survival (PFS). Interim analysis futility planned at approximately 70% 164...
To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients enrolled the ongoing ARCHER 1050 trial.In this ongoing, randomized, open-label, phase 3 trial (NCT01774721), eligible with newly diagnosed were randomized (1:1) to receive oral 45 mg/day or 250 mg/day. Randomization, by a central computer system, was stratified race mutation type (exon 19 deletion mutation/exon 21 L858R substitution mutation). The...
IntroductionLorlatinib was found to have activity in ALK-positive NSCLC a global phase 1 and 2 study. We report an ongoing study Chinese patients with advanced or metastatic NSCLC.MethodsOpen-label, dual-cohort (NCT03909971); had progressive disease after ALK tyrosine kinase inhibitor treatment (cohort 1: previous crizotinib; cohort 2: one other than crizotinib [±prior crizotinib]), more equal unirradiated extracranial target lesion, Eastern Cooperative Oncology Group performance status of 0...
Abstract Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory, anaplastic lymphoma kinase ( ALK )‐positive non‐small cell lung cancer (NSCLC). Herein, we reported the updated data on overall survival (OS) and molecular profiling from study. Methods In this study, 180 received 225 mg of orally once daily until disease progression, death or withdrawal. OS was estimated by Kaplan‒Meier...
IntroductionBy implementing dynamic circulating tumor DNA (ctDNA) analysis, we explored the impact of TP53 mutations on evolution and resistance mechanisms to ensartinib in patients with ALK-positive NSCLC.MethodsIn a multicenter phase 2 trial, NSCLC who progressed crizotinib were treated ensartinib. Blood samples for ctDNA analysis collected at baseline, cycle 3 day 1, progression disease (PD) analyzed 212-gene panel.ResultsA total 440 from 168 patients. Baseline (20.2%) significantly...
Background: Idiopathic interstitial pneumonia (IIP) can induce type II alveolar epithelial cell proliferation and pulmonary basement membrane damage subsequent release of Krebs von den Lungen-6 antigen (KL-6) to the bloodstream. This study investigated diagnostic prognostic value serum KL-6 levels for IIP.
Purpose Patients with advanced non‒small-cell lung cancer (NSCLC) who fail two lines of chemotherapy have unmet medical needs. The kinase inhibitor fruquintinib selectively targets vascular endothelial growth factor receptors and, hence, tumor angiogenesis and lymphogenesis. This randomized, double-blind, placebo-controlled, multicenter phase II trial evaluated the efficacy safety in patients nonsquamous NSCLC experienced disease progression after second-line chemotherapy. Methods Eligible...
Background: This study aimed to investigate independent risk factors of postoperative hypoxemia in patients with acute type A aortic dissection (ATAAD).Methods: single-center retrospective was conducted enrolled 75 ATAAD following surgery, which were stratified into three groups on the basis PaO2/FiO2 ratio: severe group (PaO2/FiO2 ratio ≤100 mmHg); moderate (100 mmHg < ≤200 and non-hypoxemia >200 mmHg). The patient's demography, perioperative laboratory results, operative details, clinical...
随着分子医学进展和靶向药物的不断涌现,晚期非小细胞肺癌(NSCLC)的治疗已进入到个体化治疗的时代.目前临床应用的个体化靶向治疗主要针对表皮生长因子受体(EGFR)基因突变性和间变性淋巴瘤激酶(ALK)融合基因阳性肺癌,这两种基因变异型肺癌均具有明确的分子靶点、靶点检测技术及上市的靶向药物,临床疗效得到明显提高。
To establish recommended phase II dose (RP2D) in I and evaluate safety efficacy of abivertinib patients with EGFR Thr790Met point mutation (T790M)-positive(+) non-small cell lung cancer (NSCLC) disease progression from prior inhibitors II.